The Centers for Medicare & Medicaid Services (CMS) has implemented significant changes to the payment methodology for skin substitute products beginning in CY 2026 that will significantly reduce the reimbursement for the skin substitute materials commonly used in dermatology.
The 2026 Rule Change: From Biologics to Supplies
The core of the new CMS final rule is a fundamental reclassification of the skin substitute products:
Old Model (Pre-2026)
- Classification: Billable as a Part B drug/biological.
- Payment: Separate reimbursement at ASP + 6%.
- Incentive: Financial gain tied to product selection and volume.
- Estimated Rate: Widely variable, sometimes over $2,000/sq cm.
In response to a significant increase in Medicare payments for skin substitute products, CMS says the goal of the changes is to “incentivize the use of products with the most clinical evidence of success” while protecting patient access.
New Model (Effective Jan. 1, 2026)
- Classification: An “incident-to” medical supply.
- Payment: Cost bundled into the practice expense of the graft application procedure code.
- Incentive: Fixed payment per procedure, aligning with standard of care.
- Payment Rate: $127.14 per square centimeter.
CMS acknowledges that incident-to supplies are typically included in total RVUs for procedural codes, but for CY 2026, CMS will separately pay for covered skin substitute products in the office setting. They have created three payment groups based on FDA regulatory categories (PMA, 510(k), and 361 HCT/P) but finalized a single payment rate of $127.28 per square centimeter for all three categories.
A complete list of skin substitutes and their FDA regulatory category is available on the CMS website in the PFS Federal Regulation Notices in CMS-1832-F (scroll to the CY 2026 PFS Final Rule Skin Substitute Products). Common dermatology products within these categories include Artacent, Epifix, and Puraply AM.
Documentation Guidance for Supporting Medical Necessity and Skin Substitute Codes
Payors view skin substitutes as a significant expense and require conclusive proof that they are the appropriate, cost-effective solution as compared to other options. Documentation of medical necessity should include:
1. Baseline Status: Detailed initial wound assessment and the reason skin substitutes are chosen over other methods. Including photographs will strengthen the support for medical necessity. Documenting specific measurements (length, width, depth), location, and a clear description of the wound bed is a must. The amount of skin substitute material is expected to be appropriate for the size of the wound.
2. Treatment Timeline: A chronological record of prior interventions (e.g., enzymatic debridement, standard dressings, wound closure with sutures) and their outcomes. This is especially important for chronic wound care (e.g. diabetics) but also applies to surgical wounds (e.g. post Mohs surgery). Ongoing notes that demonstrate measurable clinical improvement tied to the use of the product can further strengthen the case for use of the skin substitute products.
3. Comorbidity Documentation: How underlying conditions like diabetes, vascular disease or the nature of the wound impedes sutures and/or standard healing.
4. Product Selection Rationale: A clinician’s note explicitly stating why a particular skin substitute is required over other options, based on the wound’s characteristics and the product’s attributes.
5. Amount of Product Used and Wasted: Document the exact amount of skin substitute material that is utilized and wasted (in square cm) and the size of the package selected for the graft. If a larger than expected package size is selected that does not result in the least amount of wastage, document the rationale for selecting the larger package size (such as low inventory).
Ensuring Correct Coding
Incorrect coding is a leading cause of denials, and the 2026 changes introduce new challenges.
- Procedure Codes (CPT): Ensure the code matches the exact service (e.g., specific grafting technique, debridement) and accounts for wound size and site.
- Product Codes (HCPCS): Verify the J-code accurately reflects the specific skin substitute used.
Modifier Application
Modifier JW: Modifier -JW is appended to the J code for the skin substitute material to indicate the amount of a drug or biological that is unused and discarded from single-use packages. The discarded (or wasted) amount of the drug or biological reported with modifier -JW is eligible for payment. Bill the first line item in units with the amount utilized and bill a second line item in units with modifier -JW with the amount wasted.
Modifier -JZ: is used to attest that no amount of a drug or biological from single-dose containers or single-use packages was discarded and eligible for payment. This modifier is required by Medicare as of July 1, 2023. If there is no wastage, append modifier -JZ.
Proactive Audits and Training: Your First Line of Defense
The 2026 environment necessitates a proactive stance, where potential issues are identified and corrected internally before claims are submitted.
- Conduct Regular Internal Audits: Schedule frequent reviews of skin substitute claims. Sample charts to verify that documentation supports the codes billed and that modifiers are applied correctly.
- Invest in Targeted Staff Education: Training should be specific and ongoing. Focus sessions on the 2026 policy shifts, new/revised CPT and HCPCS codes, and evolving documentation standards from major payors.
- Foster Clinician-Coder Collaboration: Facilitate brief, regular touchpoints between providers and billing staff. When coders understand clinical intent and clinicians understand documentation requirements, claim accuracy improves dramatically.
How Compass Healthcare Consulting Guides Your Practice Through Change
Navigating these changes requires specialized expertise. Compass Healthcare Consulting provides the focused support your dermatology practice needs to turn regulatory complexity into a competitive advantage.
Our tailored services for dermatology practices include:
- Compliance-Focused Coding Audits: We go beyond basic audits to ensure your coding practices are not only accurate but also fully aligned with the latest 2026 CMS directives and defensible against payor scrutiny.
- Documentation Improvement Programs: We work directly with your providers to integrate the required specificity for wound measurement, product justification, and medical necessity into their natural workflow.
- Customized Staff Training: We provide targeted education for your billing and clinical teams on the exact policies and code changes that affect your practice’s most common procedures.
Staying ahead of compliance changes protects your revenue and allows you to focus on patient care. If you’re reviewing your practice’s readiness for the 2026 skin substitute policy shifts, our team can provide a confidential assessment. Contact Compass Healthcare Consulting today to schedule a consultation. Let’s ensure your coding and documentation practices are not just compliant, but optimized for the year ahead.
